BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...was VP of pharmaceutical sciences and Polyakova was the protein and molecular group lead at GammaDelta Therapeutics Ltd....
...growth officer from chief marketing officer. Robin Sawka, BioCentury Staff BioCentury Staff Genmab A/S Tricida Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...the University of Texas MD Anderson Cancer Center. There is growing competition in the space. GammaDelta Therapeutics Ltd....
BioCentury | Dec 20, 2019
Product Development

Rise of the first-time biotech CEO

...CEOs included device companies, the public sector and the healthcare divisions of larger technology companies. GammaDelta Therapeutics Ltd....
...you go back to that,” she said. Karen Tkach Tuzman, Associate Editor Atlas Venture Venrock Agios Pharmaceuticals Inc. Nuvelution Pharma Inc. GammaDelta Therapeutics Ltd. management first-time...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...TCR against a virus that causes adult T cell leukemia and lymphoma (No. 3216) . GammaDelta Therapeutics Ltd....
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

...Sciences Inc. (NASDAQ:GILD), bought a substantial stake in Gadeta, with an option to buy. U.K.-based GammaDelta Therapeutics Ltd....
...chairman. Targets: BTN2A - butyrophilin 2A; BTN3A - butyrophilin 3A Val Kennedy, Associate Editor ImCheck Therapeutics S.A.S. Gadeta B.V. GammaDelta Therapeutics Ltd. Pfizer...
BioCentury | Oct 16, 2019
Company News

GammaDelta spins out Adaptate to focus on antibody therapies

...time-limited option to acquire Adaptate Biotherapeutics Ltd. and has provided undisclosed funding, along with Abingworth. GammaDelta Therapeutics Ltd....
...quarter and to select its lead target in the next 12-18 months. Elizabeth S. Eaton, Staff Writer GammaDelta Therapeutics Ltd. Takeda...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...in areas that themselves are new. For example, Takeda entered a build-to-buy deal with newco GammaDelta Therapeutics Ltd....
...received an option exercise and upfront payment, and is eligible for milestones plus royalties. 9/4/17 GammaDelta Therapeutics Ltd....
...Ltd., Cambridge, U.K. Curadev Pharma Pvt. Ltd., Noida, India Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan GammaDelta Therapeutics Ltd....
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...while build-to-buys have historically been more common for single-asset or single-target companies pursuing traditional modalities, GammaDelta Therapeutics Ltd.’s...
...Crescendo Biologics Ltd., Cambridge, U.K. Francis Crick Institute, London, U.K. Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd....
...Ltd., Holytown, U.K. Targets MICA - MHC class I polypeptide-related sequence A Karen Tkach Tuzman, Associate Editor GammaDelta Therapeutics Ltd. Takeda...
BioCentury | Aug 10, 2018
Finance

Takeda gets Ambys-tious

...Capital founded Maverick in 2016. Then in May 2017, Takeda gained an option to acquire GammaDelta Therapeutics Ltd....
...flexibility to pursue more radical ideas.” Companies and Institutions Mentioned Ambys Medicines, Redwood City, Calif. GammaDelta Therapeutics Ltd....
BioCentury | Jul 20, 2018
Company News

Kite looks to Gadeta for gamma delta T cell tech

...TEG001 next quarter and submit an IND for TEG002 in 2020, Margetson said. Last year, GammaDelta Therapeutics Ltd....
...Gadeta B.V., Utrecht, the Netherlands Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Cancer Allison Johnson Gadeta B.V. GammaDelta Therapeutics Ltd. Gilead...
Items per page:
1 - 10 of 30
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...was VP of pharmaceutical sciences and Polyakova was the protein and molecular group lead at GammaDelta Therapeutics Ltd....
...growth officer from chief marketing officer. Robin Sawka, BioCentury Staff BioCentury Staff Genmab A/S Tricida Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...the University of Texas MD Anderson Cancer Center. There is growing competition in the space. GammaDelta Therapeutics Ltd....
BioCentury | Dec 20, 2019
Product Development

Rise of the first-time biotech CEO

...CEOs included device companies, the public sector and the healthcare divisions of larger technology companies. GammaDelta Therapeutics Ltd....
...you go back to that,” she said. Karen Tkach Tuzman, Associate Editor Atlas Venture Venrock Agios Pharmaceuticals Inc. Nuvelution Pharma Inc. GammaDelta Therapeutics Ltd. management first-time...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...TCR against a virus that causes adult T cell leukemia and lymphoma (No. 3216) . GammaDelta Therapeutics Ltd....
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

...Sciences Inc. (NASDAQ:GILD), bought a substantial stake in Gadeta, with an option to buy. U.K.-based GammaDelta Therapeutics Ltd....
...chairman. Targets: BTN2A - butyrophilin 2A; BTN3A - butyrophilin 3A Val Kennedy, Associate Editor ImCheck Therapeutics S.A.S. Gadeta B.V. GammaDelta Therapeutics Ltd. Pfizer...
BioCentury | Oct 16, 2019
Company News

GammaDelta spins out Adaptate to focus on antibody therapies

...time-limited option to acquire Adaptate Biotherapeutics Ltd. and has provided undisclosed funding, along with Abingworth. GammaDelta Therapeutics Ltd....
...quarter and to select its lead target in the next 12-18 months. Elizabeth S. Eaton, Staff Writer GammaDelta Therapeutics Ltd. Takeda...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...in areas that themselves are new. For example, Takeda entered a build-to-buy deal with newco GammaDelta Therapeutics Ltd....
...received an option exercise and upfront payment, and is eligible for milestones plus royalties. 9/4/17 GammaDelta Therapeutics Ltd....
...Ltd., Cambridge, U.K. Curadev Pharma Pvt. Ltd., Noida, India Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan GammaDelta Therapeutics Ltd....
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...while build-to-buys have historically been more common for single-asset or single-target companies pursuing traditional modalities, GammaDelta Therapeutics Ltd.’s...
...Crescendo Biologics Ltd., Cambridge, U.K. Francis Crick Institute, London, U.K. Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd....
...Ltd., Holytown, U.K. Targets MICA - MHC class I polypeptide-related sequence A Karen Tkach Tuzman, Associate Editor GammaDelta Therapeutics Ltd. Takeda...
BioCentury | Aug 10, 2018
Finance

Takeda gets Ambys-tious

...Capital founded Maverick in 2016. Then in May 2017, Takeda gained an option to acquire GammaDelta Therapeutics Ltd....
...flexibility to pursue more radical ideas.” Companies and Institutions Mentioned Ambys Medicines, Redwood City, Calif. GammaDelta Therapeutics Ltd....
BioCentury | Jul 20, 2018
Company News

Kite looks to Gadeta for gamma delta T cell tech

...TEG001 next quarter and submit an IND for TEG002 in 2020, Margetson said. Last year, GammaDelta Therapeutics Ltd....
...Gadeta B.V., Utrecht, the Netherlands Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Cancer Allison Johnson Gadeta B.V. GammaDelta Therapeutics Ltd. Gilead...
Items per page:
1 - 10 of 30